After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
Reminder - On Wednesday June 6, 2018 at 10:00AM PST, we will be hosting a webinar regarding the chan...
In 2016, the Procleix Panther instrument was introduced by Grifols in support of automated NAT ZIKA ...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
As a reminder, CTS will be exhibiting this weekend at the AABB Annual Meeting in San Antonio, T...
Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA test...